Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) reflecting updated views and recent competitive ...

Goldman Sachs analyst Paul Choi downgraded the stock from "Neutral" to "Sell," setting a price target of $12, which is ...

Fintel reports that on February 11, 2025, Goldman Sachs downgraded their outlook for Dynavax Technologies (NasdaqGS:DVAX) ...

Goldman Sachs downgraded Dynavax (DVAX) to Sell from Neutral with a price target of $12, down from $15. The evolving competitive landscape in ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. Receive News ...

FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis ...

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) stock from Neutral to Sell, adjusting the price target downward to $12.00 from the previous $15.00. According to InvestingPro ...

An update from Dynavax ( (DVAX) ) is now available. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company ...

June 12, 2023 — Women who used combined contraceptive pills were at greater risk of developing depression than women who did not, according to a new study. Contraceptive pills increased women's ...